Eli Lilly and Company

The provided transcript from the document "1017005-27090.pdf" does not mention any current or future new fundraising activities through debt or equity. Key points related to financial activities include: - Distribution of $1.5 billion in dividends in Q1. - Execution of $2.4 billion in share repurchases. - Active business development with several acquisitions planned or completed (Orna Therapeutics, Syntessa Pharmaceuticals, Colonia Therapeutics, Ajax Therapeutics). - No specific mention of raising new capital via debt or equity markets. Therefore, as of the information on these pages, there is no indication of new fundraising plans through debt or equity issuance.

- Lilly continues to invest heavily in pipeline development, with 42 active Phase III programs. - Increased R&D expenses by 28% in Q1 2026 to support ongoing and new product launches. - Executed multiple acquisitions to expand capabilities and pipeline: - Orna Therapeutics (in vivo CAR T for autoimmune diseases) - Sytesa Pharmaceuticals (orexin receptor 2 agonists for sleep disorders) - Colonia Therapeutics (lentiviral in vivo CAR T for multiple myeloma) - Ajax Therapeutics (next-gen JAK inhibitors for blood cancers) - Contessa Pharmaceuticals (expands neuroscience portfolio) - Launched Lilly Employer Connect, a platform to engage employers in offering obesity medications. - Committed to business development while maintaining shareholder value discipline. - Significant investments in manufacturing and commercial infrastructure to support growth in obesity and metabolic segments. - Continued expansion of direct-to-consumer digital platforms and promotional activities for obesity and incretin products.

- Full-year 2026 revenue guidance increased by $2 billion, now expected between $82 billion and $85 billion, reflecting strong momentum from Mounjaro and Semaglutide (SEB) (Page 4). - Midpoint represents 28% growth compared to 2025 (Page 4). - Continued volume-driven growth expected, fueled by expanding access and new patient starts, especially in obesity and type 2 diabetes markets (Page 7). - Foundayo's early launch indicators positive; over 20,000 patients treated with 80% new-to-class prescriptions, with further growth driven by continued promotion and expanding payer access, including Medicare from July 2026 (Pages 10-11, 15). - International markets showing rapid uptake; fully launched in over 55 countries with strong share gains despite generic competition (Page 7). - Employer Connect initiative and Medicare GLP-1 bridge program expected to drive incremental access and volume growth in U.S. employer-insured populations (Pages 2, 15). - Volume expected to expand non-linearly with price concessions but remain strong due to broad disease prevalence and growing acceptance (Page 7).

- Full year revenue guidance increased by $2 billion, now expected between $82 billion and $85 billion, representing 28% growth vs. 2025 midpoint. - Non-GAAP performance margin expected between 47% and 48.5%, driven by higher revenue. - Non-GAAP earnings per share (EPS) guidance raised to $35.50 to $37, up $2 on both ends. - Q1 non-GAAP EPS was $8.55, compared to $3.34 in Q1 2025, reflecting strong earnings growth. - Revenue growth driven by strong portfolio performance including Mounjaro and Foundayo launches. - Price expected to be a headwind in low to mid-teens percentage for the full year. - Earnings growth supported by product launches, expanded market access programs, and business development. - Incremental progress expected quarter-on-quarter, especially in expanding insurance and employer coverage.

- The upcoming Community Update Day is scheduled for Monday, December 7, with location and exact timing to be announced. - Early launch metrics for Foundayo show over 20,000 patients treated to date, with 80% of prescriptions new to class. - Commercial access for Foundayo confirmed at 2 of the large PBMs as of mid-May; Medicare access set to start in July. - Employer Connect program has positive conversations with employers but impacts on coverage likely gradual, with more opt-ins expected in 2027. - Early patient starts for Foundayo are tracking positively, with over 15,000 started in the first few weeks. - Continued strong order momentum expected through 2026, fueled by new launches and expanded market access. - No explicit numeric current orderbook or pending order volumes disclosed, but confidence expressed in ongoing growth trajectory and demand.